Table 4.
Vaccines in GBM therapy.
| SL No | Name | Clinical Trial ID | Class | Status |
|---|---|---|---|---|
| 1 | Rindopepimut | NCT01480479 | Newly diagnosed GBM (nGBM) | Phase III |
| NCT00458601 | Phase II | |||
| NCT01498328 | Recurrent GBM (rGBM) | |||
| 2 | ADU-623 | NCT01967758 | rAA, rGBM | Phase I |
| 3 | HSPPC-96 | NCT00905060 | Newly diagnosed GBM | Phase II |
| 4 | HSPPC-96 | NCT02122822 | Phase I | |
| NCT02722512 | Newly diagnosed or recurrent pediatric HGG, ependymoma | Phase I | ||
| NCT01814813 | Recurrent GBM | Phase II | ||
| NCT03018288 | Newly diagnosed GBM | |||
| 5 | IDH1 R132H Derivative | NCT02454634 | nAA, nAO, nGBM | Phase I |
| 6 | K27M peptide | NCT02960230 | Newly diagnosed GBM | |
| 7 | SurVaxM | NCT02455557 | Phase II | |
| 8 | DCs vaccine (DCVax) | NCT00045968 | Phase III | |
| 9 | DCs vaccine (DCVax) | NCT02146066 | nGBM, rGBM | Expanded access |
| 10 | DCs vaccine (brain tumor stem cells mRNA loaded) | NCT00890032 | Recurrent GBM | Phase I |
| 11 | DCs vaccine (brain tumor stem cells as antigen) | NCT01171469 | rAA, rGBM, recurrent medulloblastoma, recurrent ependymoma | |
| 12 | DCs vaccine (tumor stem cell-loaded) | NCT02820584 | Recurrent GBM | |
| 13 | DCs vaccine (fusion peptide loaded) | NCT01522820 | ||
| 14 | DCs vaccine (tumor mRNA loaded) | NCT02709616 | Newly diagnosed GBM | Phase I/II |
| 15 | DCs vaccine (pp65 RNA loaded) | NCT00639639 | Phase I | |
| 16 | DCs vaccine (pp65 RNA loaded) | NCT02465268 | Phase II | |
| NCT02366728 | ||||
| 17 | DCs vaccine (autogenic glioma stem-like cells (A2B5+) loaded) | NCT01567202 | Newly diagnosed recurrent GBM | |
| 18 | DCs vaccine (tumor lysate loaded) | NCT01204684 | nAA, rAA, nAO, rAO, nGBM, rGBM | |
| 19 | DCs vaccine (RNA loaded) | NCT00626483 | Newly diagnosed GBM | Phase I |
| 20 | DCs vaccine (tumor lysate loaded) | NCT01957956 | ||
| 21 | DCs vaccine (peptide loaded) | NCT02049489 | Recurrent GBM | |
| 22 | DCs vaccine (Wilms’ tumor 1 mRNA loaded) | NCT02649582 | Newly diagnosed GBM | Phase I/II |
| 23 | DCs vaccine + tumor lysate boost | NCT01808820 | rAA, rGBM | Phase I |
| 24 | DCs vaccine (allogenic GBM stem-like cell lysate loaded) | NCT02010606 | Newly diagnosed and recurrent GBM | |
| 25 | DCs vaccine (tumor lysate loaded)+ nivolumab | NCT03014804 | Recurrent GBM | Phase II |
| 26 | Vaccine derived from tumor lysate | NCT01400672 | Phase I | |
| 27 | HSCs, DCs vaccine, CTLs | NCT01759810 | Phase II/III | |
| 28 | Bevacizumab and TAA, Poly-ICLC, KLH | NCT02754362 | Phase II | |
| 29 | SL-701, poly-ICLC, bevacizumab | NCT02078648 | Phase I/II | |
| 30 | ICT-107 | NCT02546102 | Newly diagnosed GBM | Phase III |
| 31 | IMA950, Poly ICLC | NCT01920191 | Phase I/II | |
| 32 | IMA950, GM-CSF | NCT01222221 | Phase I | |
| 33 | Personalized peptide vaccine, Poly ICLC | NCT02510950 | Phase 0 |